Program
andamertinib
Also written as “PLB1004”, “PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy” and “RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Avistone Biotechnology | 87 open or running | phase 3since Jan 31, 2024 | Apr 13, 2022 | Nov 2026phase 2 · NCT07336732 |
| Avistone Pharmaceutical(Ningbo) | 11 open or running | phase 2since Jun 24, 2025 | Jun 24, 2025 | Mar 8, 2028phase 2 · NCT07063329 |
| Beijing Pearl Biotechnology Limited Liability | 11 open or running | phase 2since Nov 4, 2025 | Nov 4, 2025 | Dec 2029phase 2 · NCT07285148 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 13, 2022First study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Avistone BiotechnologyAvistone Biotechnology · NCT05347628 · 91 enrolled · China
- Aug 18, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06015503 · 139 enrolled · China
- Sep 6, 2023Phase 1 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06046495 · 81 planned · United States
- Jan 31, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06281964 · 327 planned · China
- Mar 21, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06343064 · 156 planned · China
- Aug 25, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06574347 · 120 planned · China
- Apr 25, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06970782 · 278 planned
- Jun 24, 2025Avistone Pharmaceutical(Ningbo)'s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Avistone Pharmaceutical(Ningbo)Avistone Pharmaceutical(Ningbo) · NCT07063329 · 108 planned · China
- Nov 4, 2025Beijing Pearl Biotechnology Limited Liability's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Beijing Pearl Biotechnology Limited LiabilityBeijing Pearl Biotechnology Limited Liability · NCT07285148 · 253 planned · United States
- Dec 18, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT07336732 · 40 planned · China
Ahead
- Nov 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT07336732
- Dec 31, 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06343064
- Dec 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06970782
- Feb 9, 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06046495
TargetBeta
“An orally bioavailable, mono-anilino-pyrimidine, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, ”NCIt, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| befotertinibrule | Betta Pharmaceuticals | phase 3 | 6 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07336732Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Avistone Biotechnology | Nov 2026 | 40 |
| NCT07285148Carcinoma, Non-Small-Cell Lung · United States | 2 | Not yet recruiting | Beijing Pearl Biotechnology Limited Liability | Dec 2029 | 253 |
| NCT07063329Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Avistone Pharmaceutical(Ningbo) | Mar 8, 2028 | 108 |
| NCT06970782Carcinoma, Non-Small-Cell Lung | 3 | Not yet recruiting | Avistone Biotechnology | Dec 31, 2027 | 278 |
| NCT06574347Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Avistone Biotechnology | Oct 31, 2026 | 120 |
| NCT06343064Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Avistone Biotechnology | Dec 31, 2026 | 156 |
| NCT06281964Carcinoma, Non-Small-Cell Lung · China | 3 | By invitation | Avistone Biotechnology | Jun 30, 2028 | 327 |
| NCT06046495Carcinoma, Non-Small-Cell Lung · United States | 1 | Recruiting | Avistone Biotechnology | Feb 9, 2028 | 81 |
| NCT06015503Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | Avistone Biotechnology | Mar 6, 2025 | 139 |
| NCT05347628Carcinoma, Non-Small-Cell Lung · China | 1 | UNKNOWN | Avistone Biotechnology | Apr 4, 2023 | 91 |
How it is read
Names in the registry
- “PLB1004”, 8 entries
- “PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy”, 2 entries
- “RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy”, 2 entries
- “ANS014004 + PLB1004”, 1 entry
Codes read as this program: PLB1004.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 10 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.